FINWIRES · TerminalLIVE
FINWIRES

HKG:2196

32 stories mentioning HKG:2196Updated just now

Every FINWIRES story that references HKG:2196, newest first.

What's the latest news on HKG:2196?

Asia

Fosun Pharma Unit Passes GMP Inspection

Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) subsidiary, Shanghai Henlius Biotech (HKG:2696), passed a drug GMP or good manufacturing practice inspection, according to a Shanghai bourse filing on Thursday.The Shanghai Municipal Medical Products Administration made the inspection at Henlius' manufacturing facility in Songjiang District, which produces the breast cancer drug Hanbeiyou or pertuzumab injection.The company was found to be compliant with GMP requirements.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.

HKG:2196HKG:2696SHA:600196
Asia

Fosun Pharma Gets China Nod to Trial HLX3902 Injection

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through its subsidiary Shanghai Henlius Biotech (HKG:2696), received approval from China's National Medical Products Administration for the clinical trials of HLX3902 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for metastatic castration-resistant prostate cancer and other advanced solid tumors.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.

HKG:2196HKG:2696SHA:600196
Asia

Fosun Pharma Unit's Luvometinib Gets China Nod for Langerhans Cell Histiocytosis Drug Indication

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical to Invest 414 Million Yuan in Xingyao Kunze's Series B Funding Round

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through subsidiary Fosun Pharma Industry, plans to invest 414.4 million yuan to participate in the Series B financing of Xingyao Kunze, according to a Wednesday filing on the Shanghai bourse.Xingyao Kunze develops drugs for liver diseases. Its pipeline products are HT-101 and HT-102, and the combination of these drugs.After the completion of the funding round, Fosun Pharma Industry is expected to own 20.9% of Xingyao Kunze.The pharmaceutical company's Hong Kong shares fell by less than 2% during the afternoon trade.

HKG:2196SHA:600196
Asia

Fosun Pharma Gets Registration Nod for Infection Drug in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.

HKG:2196SHA:600196
Asia

Fosun Pharma Secures $60 Million Option for Alzheimer's Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.

HKG:2196SHA:600196
Asia

Fosun Pharma's Unit's Registration Application for Blood Stasis Syndrome Drug Accepted in China

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Approval for Antidepressant Application

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit's drug registration application for Venlafaxine Hydrochloride Sustained-release Tablets obtained approval from China's National Medical Products Administration.The approved indication for the drug, developed by Fosun Pharma (Xuzhou), is to treat depression and generalized anxiety disorder, according to a Friday Hong Kong bourse filing.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Acute Heart Failure Drug Registration

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application for the Sodium Nitroprusside Injection was approved by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approved indication is for hypertensive emergencies and acute heart failure.

HKG:2196SHA:600196
Asia

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology obtained approval for a phase I/II clinical trial of FKC289 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug will be tested for the treatment of primary light chain amyloidosis and membranous nephropathy.The subsidiary will begin the trial once conditions are met.

HKG:2196SHA:600196
Asia

Fosun Pharma Unit Gets China Nod to Register Analgesia Drug

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application of Flurbiprofen Axetil Injection was approved by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indication is for post-surgical and cancer-related analgesia.

HKG:2196SHA:600196

Showing 21-32 of 32

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2196 in your portfolio
WheelAI
WheelAI
Analyze HKG:2196 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2196